{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=2", "query": { "intervention": "0.9% Sodium Chloride (NaCl)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1980, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T21:49:36.776Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07224711", "title": "The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain", "Post Operative Analgesia", "Opioid Consumption, Postoperative" ], "interventions": [ { "name": "Lidocaine HCl 0.8% in D5W", "type": "DRUG" }, { "name": "Sodium Chloride 0.9%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2290, "start_date": "2026-10-31", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224711" }, { "nct_id": "NCT01729299", "title": "Ghrelin Effect on Beta Cell Function in Health and Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Exendin (9-39)", "type": "DRUG" }, { "name": "acyl ghrelin", "type": "DRUG" }, { "name": "saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Dalessio", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2013-04", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729299" }, { "nct_id": "NCT01658501", "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "50 mg PB1023", "type": "DRUG" }, { "name": "70 mg PB1023", "type": "DRUG" }, { "name": "100 mg PB1023", "type": "DRUG" }, { "name": "Placebo (0.9% Sodium Chloride)", "type": "DRUG" }, { "name": "Victoza®", "type": "DRUG" }, { "name": "Diet and Exercise", "type": "OTHER" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulfonylurea", "type": "DRUG" }, { "name": "Metformin and Sulfonylurea", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 593, "start_date": "2012-07", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 93, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658501" }, { "nct_id": "NCT07246863", "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-Squamous Non-Small Cell Lung Cancer", "Adult Solid Tumor" ], "interventions": [ { "name": "Visugromab RDE (recommended dose for expansion)", "type": "BIOLOGICAL" }, { "name": "Visugromab 6mg/kg", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo Saline Infusion", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "CatalYm GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2025-10-07", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07246863" }, { "nct_id": "NCT06060457", "title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "Fluzone HD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1900, "start_date": "2023-09-25", "completion_date": "2024-06-07", "has_results": true, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 34, "location_summary": "Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Dublin", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06060457" }, { "nct_id": "NCT05428007", "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Ipilimumab Injection", "type": "DRUG" }, { "name": "Nivolumab/Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 105, "start_date": "2023-02-02", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428007" }, { "nct_id": "NCT03623022", "title": "Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Clinical Center Reference Endotoxin (CCRE)", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 15, "start_date": "2018-10-17", "completion_date": "2019-09-17", "has_results": false, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03623022" }, { "nct_id": "NCT04796896", "title": "A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "mRNA-1273.214", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Months to 11 Years" }, "enrollment_count": 11942, "start_date": "2021-03-15", "completion_date": "2024-03-15", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Banning", "state": "California" }, { "city": "El Monte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04796896" }, { "nct_id": "NCT02570503", "title": "Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "Ropivacaine", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" }, { "name": "Clonidine", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "0.9% sodium chloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2015-10", "completion_date": "2021-02-11", "has_results": true, "last_update_posted_date": "2022-03-04", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02570503" }, { "nct_id": "NCT03811951", "title": "Neuro Biomarkers of Smoking Behavior", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Novolin R", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "21 Years to 40 Years" }, "enrollment_count": 4, "start_date": "2018-09-12", "completion_date": "2019-09-27", "has_results": true, "last_update_posted_date": "2021-03-02", "last_synced_at": "2026-10-08T21:49:36.776Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03811951" } ] }